OrbiMed’s argenx ARGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $86.2M | Sell |
92,880
-44,020
| -32% | -$36.3M | 1.6% | 12 |
|
|
2026
Q1 | $100M | Sell |
136,900
-9,100
| -6% | -$7.12M | 1.98% | 13 |
|
|
2025
Q4 | $123M | Sell |
146,000
-26,300
| -15% | -$22.5M | 2.51% | 10 |
|
|
2025
Q3 | $127M | Sell |
172,300
-35,700
| -17% | -$23.5M | 2.99% | 10 |
|
|
2025
Q2 | $115M | Buy |
208,000
+1,300
| +0.6% | +$754K | 2.86% | 10 |
|
|
2025
Q1 | $122M | Buy |
206,700
+17,000
| +9% | +$10.7M | 2.92% | 8 |
|
|
2024
Q4 | $117M | Sell |
189,700
-14,800
| -7% | -$8.67M | 2.4% | 10 |
|
|
2024
Q3 | $111M | Sell |
204,500
-4,600
| -2% | -$2.32M | 2.01% | 13 |
|
|
2024
Q2 | $89.9M | Buy |
209,100
+57,500
| +38% | +$22M | 1.78% | 15 |
|
|
2024
Q1 | $59.7M | Buy |
151,600
+67,000
| +79% | +$26M | 1.09% | 29 |
|
|
2023
Q4 | $32.2M | Buy |
84,600
+52,000
| +160% | +$24.2M | 0.64% | 53 |
|
|
2023
Q3 | $16M | Hold |
32,600
| – | – | 0.34% | 68 |
|
|
2023
Q2 | $12.7M | Sell |
32,600
-11,900
| -27% | -$4.68M | 0.23% | 81 |
|
|
2023
Q1 | $16.6M | Buy |
44,500
+28,300
| +175% | +$10.5M | 0.33% | 73 |
|
|
2022
Q4 | $6.14M | Sell |
16,200
-253,500
| -94% | -$94.8M | 0.12% | 88 |
|
|
2022
Q3 | $95.2M | Buy |
269,700
+75,700
| +39% | +$28M | 1.77% | 21 |
|
|
2022
Q2 | $73.5M | Buy |
194,000
+24,200
| +14% | +$7.79M | 1.33% | 26 |
|
|
2022
Q1 | $53.5M | Buy |
+169,800
| New | +$49.4M | 0.87% | 38 |
|
|
2020
Q2 | – | Sell |
-28,591
| Closed | -$3.77M | – | 138 |
|
|
2020
Q1 | $3.77M | Sell |
28,591
-227,709
| -89% | -$33.3M | 0.06% | 113 |
|
|
2019
Q4 | $41.1M | Sell |
256,300
-54,100
| -17% | -$7.32M | 0.59% | 51 |
|
|
2019
Q3 | $35.4M | Hold |
310,400
| – | – | 0.67% | 46 |
|
|
2019
Q2 | $43.9M | Sell |
310,400
-50,900
| -14% | -$6.46M | 0.68% | 44 |
|
|
2019
Q1 | $45.1M | Sell |
361,300
-286,300
| -44% | -$33.7M | 0.7% | 42 |
|
|
2018
Q4 | $62.2M | Sell |
647,600
-71,200
| -10% | -$6.33M | 1.15% | 27 |
|
|
2018
Q3 | $54.5M | Buy |
718,800
+119,500
| +20% | +$10.6M | 0.66% | 45 |
|
|
2018
Q2 | $49.7M | Buy |
599,300
+99,300
| +20% | +$8.88M | 0.59% | 52 |
|
|
2018
Q1 | $40.2M | Hold |
500,000
| – | – | 0.5% | 58 |
|
|
2017
Q4 | $31.6M | Hold |
500,000
| – | – | 0.4% | 68 |
|
|
2017
Q3 | $11.3M | Hold |
500,000
| – | – | 0.11% | 103 |
|
|
2017
Q2 | $10.6M | Buy |
+500,000
| New | +$10.4M | 0.11% | 98 |
|
Other funds holding ARGX
JT
ACA
RI
OrbiMed's ARGX Position: Q2 2026 in Review
OrbiMed reduced its argenx (ARGX) stake by 32% in Q2 2026, selling an estimated $36.3M and leaving 92,880 shares worth $86.2M. The position accounts for 1.6% of the portfolio, ranked #12.
OrbiMed first reported a position in ARGX in Q2 2017 and has held it in 30 quarters since. The position peaked at $127M in Q3 2025. 506 funds tracked by Wall St. Rank hold ARGX as of Q2 2026.
- OrbiMed held 92,880 shares of argenx worth $86.2M as of Q2 2026.
- OrbiMed sold 44,020 argenx shares in Q2 2026, an estimated $36.3M.
- argenx made up 1.6% of OrbiMed's portfolio in Q2 2026, its #12 holding.
- OrbiMed first reported a position in argenx in Q2 2017 and has held it in 30 quarters since.
- OrbiMed's argenx position peaked at $127M in Q3 2025.
- 506 funds tracked by Wall St. Rank held argenx as of Q2 2026.
Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.